Philadelphia-positive myelogenous leukemia
diseaseOn this page
Also known as Ph1-positive granulocytic leukaemiaPh1-positive granulocytic leukemiaPh1-positive myelocytic leukaemiaPh1-positive myelocytic leukemiaPh1-positive myelogenous leukaemiaPh1-positive myelogenous leukemiaPh1-positive myeloid leukaemiaPh1-positive myeloid leukemiaPhiladelphia-positive granulocytic leukaemiaPhiladelphia-positive granulocytic leukemiaPhiladelphia-positive myelocytic leukaemiaPhiladelphia-positive myelocytic leukemiaPhiladelphia-positive myeloid leukaemiaPhiladelphia-positive myeloid leukemia
Summary
Philadelphia-positive myelogenous leukemia (MONDO:0024685) is a cancer and 2 clinical trials. Top therapeutic interventions include dasatinib anhydrous. A subtype of myeloid leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Philadelphia-positive myelogenous leukemia |
| Mondo ID | MONDO:0024685 |
| NCIT | C3177 |
| UMLS | C0023476 |
| MedGen | 9731 |
| GARD | 0025459 |
| Is cancer (heuristic) | yes |
Also known as: Ph1-positive granulocytic leukaemia · Ph1-positive granulocytic leukemia · Ph1-positive myelocytic leukaemia · Ph1-positive myelocytic leukemia · Ph1-positive myelogenous leukaemia · Ph1-positive myelogenous leukemia · Ph1-positive myeloid leukaemia · Ph1-positive myeloid leukemia · Philadelphia-positive granulocytic leukaemia · Philadelphia-positive granulocytic leukemia · Philadelphia-positive myelocytic leukaemia · Philadelphia-positive myelocytic leukemia · Philadelphia-positive myelogenous leukemia · Philadelphia-positive myeloid leukaemia · Philadelphia-positive myeloid leukemia
Disease family
This is a subtype of myeloid leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › myeloid leukemia › Philadelphia-positive myelogenous leukemia
Related subtypes (3): atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myeloid leukemia, acute myeloid leukemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00101660 | PHASE2 | COMPLETED | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib |
| NCT00103844 | PHASE2 | COMPLETED | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DASATINIB ANHYDROUS | 4 | 4 |
| CHEMBL4583196 | 0 | 2 |
Related Atlas pages
- Drugs: Dasatinib